Fresenius Group Overview

Results Center

To archive

Q3/2018 Results

Fresenius in Q3/18 with continued strong Group earnings growth in constant currency
  • Excellent performance of Fresenius Kabi across all regions and product categories
  • Fresenius Medical Care’s sales and earnings growth below the Company’s expectations
  • Preparatory initiatives for expected regulatory requirements and decline in admissions impact Helios Germany; Helios Spain with steady yet dynamic growth
  • Strong momentum in both Vamed’s project and service businesses

Selected Key Figures Q3/2018

Key figures Q3 2018

 

1 Adjusted for IFRS 15 adoption and divestitures of Care Coordination activities

2 In constant currency

3 Before special items

4 Before divestitures of Care Coordination activities

 

Archive